Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation

Disclosures: - This work was supported by NIH grant CA167708-01, and Leukemia and Lymphoma Society of America award #6472-15. - ABT-737 and ABT-199 used in these studies were provided by Abbott laboratories.

Contributions: SG was the principal investigator and takes primary responsibility for the paper; he designed the research, recruited the patients and wrote the manuscript. MR designed, coordinated, and performed the research, analyzed data and wrote the manuscript. MMA, EH, REP, MR, MK, LBR, performed the laboratory work for this study. KAR, CID, and AFG analyzed data. The authors report no potential conflicts of interest.